SCHEMBL830647

SCHEMBL830647

COc1ccc(/C=C/C(=O)CS(=O)(=O)c2cc3cc(Cl)ccc3oc2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAOB P27338 8/20 0.49
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
RXFP1 Q9HBX9 1/20 0.49
CA12 O43570 4/20 0.48
CA9 Q16790 4/20 0.48
GSK3B P49841 1/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
MAOA P21397 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CA3 P07451 1/20 0.42
HPGD P15428 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830648 1.00 MEN1 (0.51) MEN1KMT2AMAOBCA1CA2
SCHEMBL830822 1.00 MEN1 (0.51) MEN1KMT2AMAOBCA1CA2
SCHEMBL830642 0.92 MAOB (0.54) MEN1KMT2AMAOBCA1CA2
SCHEMBL829482 0.92 MAOB (0.54) MEN1KMT2AMAOBCA1CA2
SCHEMBL829481 0.92 MAOB (0.54) MEN1KMT2AMAOBCA1CA2
SCHEMBL829855 0.89 POLB (0.57) MEN1KMT2AMAOBCA1CA2
SCHEMBL830056 0.89 RXFP1 (0.49) KMT2AMAOBCA1CA2RXFP1
SCHEMBL830057 0.89 RXFP1 (0.49) KMT2AMAOBCA1CA2RXFP1
SCHEMBL830905 0.89 POLB (0.57) MEN1KMT2AMAOBCA1CA2
SCHEMBL829856 0.89 POLB (0.57) MEN1KMT2AMAOBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US claimed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 MEN1 979/4885KMT2A 484/4885MAOB 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.